Share Information

ChromoGenics AB (publ) is a “Euroclear company” and the shares are electronically registered, the share register is kept by Euroclear Sweden AB, Klarabergsviadukten 63, 111 64 Stockholm.

The company’s shares are listed on Nasdaq First North Stockholm since March 23, 2017.

All shares are of the same class, have equal rights to share the Company’s assets and profits and have one vote each without any special limitations.

Share capital on March 31, 2019 amounted to SEK 34 551 198 distributed over 172 755 980 shares with a quota value of SEK 0.2 per share.
ChromoGenics’ shares and warrants are traded on NASDAQ First North Stockholm.

Trading Information

Share
ISIN-code: SE0009496268

LEI-code: 549300ULKN252K60BG25

Short name: CHRO

Only one share category exists.

Warrants series TO2

ISIN-code: SE0010662395

Short name: CHRO TO2

Subscription period:10-31 January 2020

Dividend Policy

In Swedish companies, the dividend must be proposed by the Board and decided by the Annual General Meeting in accordance with the Companies Act and the Articles of Association.

In consideration of proposals for future dividends, the Board will consider several factors, including the Company’s operations, operating profit and financial position, current and expected liquidity needs, expansion plans, contractual constraints and other significant factors.

ChromoGenics is in a development and expansion phase and therefore no dividend has ever been paid. At present, the Board intends to continue to allow the Company to balance any profits to finance the growth and operation of the business and consequently does not predict that any cash dividends will be paid in the foreseeable future.

Ownership

Each share in ChromoGenics entails one (1) vote at the Annual General Meeting.
Largest owners as of March 29, 2019

Aktieägare eng 2019-03-29

Warrant Programs

Warrant program_1

1) Both warrant programs are part of a unit issue with the right to subscribe to one share and one warrant that targets key staff and some owners and deviates from the shareholders’ preferential rights.

As a result of the rights issue in January 2018, the warrants have been recalculated so that each warrant entitles to subscription of 1,03 share to a redemption price of 5,22 SEK before the respective maturity dates. (earlier 1 share to redemption price of 5,40 SEK)

2) In connection with the acquisition of I-window International AB, 2,000,000 warrants were issued to I-window International AB and registered at the Swedish Companies Registration Office on September 12, 2018. The warrants can be exercised to SEK 2 per share and matures on December 31, 2021.

Warrant _2

1) Warrants were issued in combination with a rights issue performed during January 2018.  18,974,669 warrants (TO2) were registered at the Swedish Companies Registration Office on February 21, 2018. One (1) warrant (TO2) entitles to subscription of one (1) new share to the price of 3,50 SEK during the period January 10-31, 2020.

As a result of the share issue that was carried out in February 2019 the warrants TO2 will be recalculated. After recalculation every warrant of series TO2 will entitle to subscribe 1.62 shares at a price of 2.17 SEK. Maximally 30 655 062 shares will be issued which correspond to a dilution of 17.7 percent. With full utilization of the warrants, additional capital of SEK 66.4 million will be brought to the company.

 

 

Certified Adviser

G&W Fondkommission has been appointed Certified Adviser for ChromoGenics.

G&W Fondkommission
Kungsgatan 3
111 43 Stockholm
Tel: 08-503 000 50
www.gwkapital.se

IR contact

Lars Ericsson
CFO & Head of Communications
+46 705 497 644
Email

  • co-fin-emh_logotyp

Subscribe

Subscribe to our news